Abstract
The ENDURANCE Supplemental trial was designed to assess the effectiveness of an enhanced blood pressure (BP) management protocol in reducing the occurrence of neurological events in patients ineligible for cardiac transplantation receiving the Medtronic HeartWareTM HVADTM System. The trial demonstrated that enhanced BP management significantly reduced the mean arterial pressure (MAP) and the incidence of hemorrhagic strokes compared to the original ENDURANCE trial. This subsequent analysis sought to understand the effects of BP management on stroke severity and recovery.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
